Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in lactotrophs | 0.75 |
| chemistry Open Targets | compounds already reach it: balipodect, pbf-999, pentoxifylline +3 | 1.00 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 54 Parkinson's papers of 567 | 0.47 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2951
Sealed predictions
- PDE10A in dopamine neurons, braak+0.52 (p 0.151) → +0.11 (p 0.777)receipt 2957
Swarm cases
receipt 2957: PDE10A in dopamine neurons, braak
- power
- full sample +0.32 (p 0.198, n 18), 95% CI -0.17 to +0.68. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.33 (p 0.176, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.34 (p 0.170, n 18). could be the mix.
- skeptic
- leave-one-out range +0.24 to +0.49, sign flips 0; without severely affected donors +0.32 (p 0.198, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PDE10A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts